VARLI, B. Et Al. 2021. Anorexigenic peptide (leptin, obestatin, nesfatin-1) levels and their impact on assisted reproductive technology treatment outcomes in patients with polycystic ovary syndrome. CLINICAL AND EXPERIMENTAL REPRODUCTIVE MEDICINE , vol.48, no.4 , 368-373.

VARLI, B., ŞÜKÜR, Y. E., ÖZMEN, B., Ergüder, B. İ., SÖNMEZER, M., BERKER, B., ... Atabekoğlu, C.(2021). Anorexigenic peptide (leptin, obestatin, nesfatin-1) levels and their impact on assisted reproductive technology treatment outcomes in patients with polycystic ovary syndrome. CLINICAL AND EXPERIMENTAL REPRODUCTIVE MEDICINE , vol.48, no.4, 368-373.

VARLI, BULUT Et Al. "Anorexigenic peptide (leptin, obestatin, nesfatin-1) levels and their impact on assisted reproductive technology treatment outcomes in patients with polycystic ovary syndrome," CLINICAL AND EXPERIMENTAL REPRODUCTIVE MEDICINE , vol.48, no.4, 368-373, 2021

VARLI, BULUT Et Al. "Anorexigenic peptide (leptin, obestatin, nesfatin-1) levels and their impact on assisted reproductive technology treatment outcomes in patients with polycystic ovary syndrome." CLINICAL AND EXPERIMENTAL REPRODUCTIVE MEDICINE , vol.48, no.4, pp.368-373, 2021

VARLI, B. Et Al. (2021) . "Anorexigenic peptide (leptin, obestatin, nesfatin-1) levels and their impact on assisted reproductive technology treatment outcomes in patients with polycystic ovary syndrome." CLINICAL AND EXPERIMENTAL REPRODUCTIVE MEDICINE , vol.48, no.4, pp.368-373.

@article{article, author={BULUT VARLI Et Al. }, title={Anorexigenic peptide (leptin, obestatin, nesfatin-1) levels and their impact on assisted reproductive technology treatment outcomes in patients with polycystic ovary syndrome}, journal={CLINICAL AND EXPERIMENTAL REPRODUCTIVE MEDICINE}, year=2021, pages={368-373} }